JP2015521050A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521050A5
JP2015521050A5 JP2015515598A JP2015515598A JP2015521050A5 JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5 JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5
Authority
JP
Japan
Prior art keywords
maf
subject
expression level
copy number
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015515598A
Other languages
English (en)
Japanese (ja)
Other versions
JP6386450B2 (ja
JP2015521050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/001859 external-priority patent/WO2013182912A2/en
Publication of JP2015521050A publication Critical patent/JP2015521050A/ja
Publication of JP2015521050A5 publication Critical patent/JP2015521050A5/ja
Application granted granted Critical
Publication of JP6386450B2 publication Critical patent/JP6386450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015515598A 2012-06-06 2013-06-06 肺がん転移の診断、予後診断および処置のための方法 Active JP6386450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656372P 2012-06-06 2012-06-06
US61/656,372 2012-06-06
PCT/IB2013/001859 WO2013182912A2 (en) 2012-06-06 2013-06-06 Method for the diagnosis, prognosis and treatment of lung cancer metastasis

Publications (3)

Publication Number Publication Date
JP2015521050A JP2015521050A (ja) 2015-07-27
JP2015521050A5 true JP2015521050A5 (enExample) 2016-08-04
JP6386450B2 JP6386450B2 (ja) 2018-09-05

Family

ID=49237517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515598A Active JP6386450B2 (ja) 2012-06-06 2013-06-06 肺がん転移の診断、予後診断および処置のための方法

Country Status (13)

Country Link
US (2) US10006091B2 (enExample)
EP (2) EP3467124A1 (enExample)
JP (1) JP6386450B2 (enExample)
KR (1) KR102226219B1 (enExample)
CN (1) CN104603288B (enExample)
AU (2) AU2013273242B2 (enExample)
BR (1) BR112014030750A2 (enExample)
CA (1) CA2875918A1 (enExample)
DK (1) DK2859120T3 (enExample)
ES (1) ES2705237T3 (enExample)
MX (1) MX368513B (enExample)
TR (1) TR201819859T4 (enExample)
WO (1) WO2013182912A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2888122A1 (en) * 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
US20160032400A1 (en) * 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
CN106795557A (zh) * 2014-06-02 2017-05-31 瓦利保健系统公司 用于肺癌诊断的方法和系统
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CA2978941A1 (en) * 2015-03-12 2016-09-15 Moerae Matrix, Inc. Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
CN105154542B (zh) * 2015-09-01 2018-04-17 杭州源清生物科技有限公司 一组用于肺癌分子分型的基因及其应用
EP4086285A1 (en) * 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
EP3454866A4 (en) * 2016-05-13 2020-01-08 Golden Biotechnology Corporation METHOD AND COMPOSITIONS FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER
WO2017201043A1 (en) * 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer
CA3025264A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
CN106055921A (zh) * 2016-05-27 2016-10-26 华中农业大学 基于基因表达和药物靶标的药物活性预测与筛选方法
CN106119405B (zh) * 2016-08-31 2019-11-12 广州万德基因医学科技有限公司 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用
CN107058480B (zh) * 2016-12-14 2018-07-13 河北医科大学第四医院（河北省肿瘤医院） 用于诊断肺腺癌的长链非编码rna标志物
CN106815486B (zh) * 2017-01-22 2021-06-04 华中农业大学 一种个性化用药的系统药理学方法
CN107058499B (zh) * 2017-01-25 2020-03-13 河北医科大学第四医院（河北省肿瘤医院） 一种用于肺腺癌诊治的分子标志物
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
WO2019152788A1 (en) * 2018-02-02 2019-08-08 Morgan And Mendel Genomics, Inc. Robust genomic predictor of breast and lung cancer metastasis
KR102218199B1 (ko) 2019-01-31 2021-02-22 중앙대학교 산학협력단 폐암 전이 예측용 바이오마커 조성물
CN110157792A (zh) * 2019-04-22 2019-08-23 中山大学孙逸仙纪念医院 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用
CN110093422A (zh) * 2019-05-24 2019-08-06 中国人民解放军西部战区总医院 Linc02159在肺腺癌诊疗中的应用
KR102260915B1 (ko) * 2020-02-19 2021-06-04 한국원자력의학원 폐암의 방사선 치료 예후 예측을 위한 생체 표지자
CN119143798B (zh) * 2024-08-01 2025-09-30 河北医科大学 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用
CN119876392B (zh) * 2025-01-06 2025-08-12 上海市第六人民医院 一种用于辅助诊断肺腺癌骨转移的生物标志物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
EA200100972A1 (ru) 1999-03-15 2002-02-28 Аксис Фармасьютикалз, Инк. Новые соединения и композиции как ингибиторы протеаз
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
EP1356093A2 (en) * 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
WO2005060722A2 (en) 2003-12-18 2005-07-07 President And Fellows Of Hardvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
CA2623405C (en) 2005-09-20 2014-11-25 Immunivest Corporation Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
US20080219996A1 (en) * 2005-09-26 2008-09-11 Thea Kalebic Molecular Markers Associated with Bone Metastasis
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
AU2008314459A1 (en) 2007-10-18 2009-04-23 University Health Network Clioquinol for the treatment of hematological malignancies
US20110144155A1 (en) 2008-06-06 2011-06-16 Schimmer Aaron D 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
US8728738B2 (en) * 2008-07-02 2014-05-20 Assistance Publique-Hopitaux De Paris Method for predicting clinical outcome of patients with non-small cell lung carcinoma
ES2562274T3 (es) * 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
AU2012211964A1 (en) 2011-02-04 2013-08-22 Bioarray Genetics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032400A1 (en) * 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
EP3524698A1 (en) 2013-10-09 2019-08-14 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the prognosis and treatment of cancer metastasis
BR112016029558A2 (pt) 2014-06-17 2017-08-22 Igenomix S L terapia de células-tronco em patologias endometriais
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CA3025264A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Similar Documents

Publication Publication Date Title
Meng et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
JP2016516403A5 (enExample)
Thomas et al. Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease
Liu et al. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma
JP2015520606A5 (enExample)
WO2013182912A4 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
Shames et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck
Shi et al. Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer
JP2016105731A5 (enExample)
JP2016539625A5 (enExample)
JP5690588B2 (ja) 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
Cui et al. LncRNA FAM230B promotes gastric cancer growth and metastasis by regulating the miR-27a-5p/TOP2A axis
Al-Khanbashi et al. Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment
Hung et al. Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma
JP2018078911A5 (enExample)
JP2013541339A5 (enExample)
Sahay et al. The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer
JP2012522756A5 (enExample)
JP6931926B2 (ja) 遺伝子発現プロファイル及び乳癌におけるその使用
Davidson et al. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
JP2008536480A5 (enExample)
EP3215635A1 (en) Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis
WO2010101916A1 (en) Methods for predicting cancer response to egfr inhibitors
JP2014533960A5 (enExample)
Pan et al. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma